{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"164"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3789"},{"groupId":"OG001","value":"3787"}],"units":"Participants"}],"description":"Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver.","groups":[{"description":"Patients receive oral exemestane (25 mg) once daily for 5 years.\n\nexemestane: Given orally","id":"OG000","title":"Exemestane"},{"description":"Patients receive oral anastrozole (1 mg) once daily for 5 years.\n\nanastrozole: Given orally","id":"OG001","title":"Anastrozole"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent to treat","reportingStatus":"POSTED","timeFrame":"5 years","title":"Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence","type":"SECONDARY","unitOfMeasure":"Participants"}